Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock

In this article:
  • Chardan has initiated coverage on EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and a price target of $21 based on the company's commercial potential with its lead EYP-1901 for Wet Age-related macular degeneration (AMD).

  • The price target represents an upside of over 160%.

  • The lead program utilizes a bioerodible Durasert formulation. Durasert technology is a micro-implant that can be injected intravitreally in an office setting.

  • Related: EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss.

  • Once injected, it releases a therapeutic at a controlled rate over an extended period, from weeks to months.

  • Chardan writes that Durasert technology is well-validated, with four products approved to date.

  • Durasert provides for zero-order release kinetics, meaning that vorolanib is released at a nearly constant rate over the implant's life.

  • Price Action: EYPT shares are up 2.37% at $7.98 during the market session on the last check Thursday.

Latest Ratings for EYPT

Date

Firm

Action

From

To

Nov 2021

HC Wainwright & Co.

Maintains

Buy

May 2021

HC Wainwright & Co.

Maintains

Buy

Jan 2021

Cantor Fitzgerald

Initiates Coverage On

Overweight

View More Analyst Ratings for EYPT

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement